JP Morgan Chase
NMTC icon

JP Morgan Chase’s NeuroOne Medical Technologies NMTC Stock Holding History

JP Morgan Chase’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$52 – 7466
2025
Q1 		$52 Sell
10
-1
-9% -$6 ﹤0.01% 6981
2024
Q4 		$55 Sell
11
-1
-8% -$5 ﹤0.01% 7110
2024
Q3 		$68 Buy
12
+2
+20% +$10 ﹤0.01% 7066
2024
Q2 		$46 Buy
10
+1
+11% +$6 ﹤0.01% 7042
2024
Q1 		$66 Buy
9
+2
+29% +$15 ﹤0.01% 6977
2023
Q4 		$62 Buy
7
+3
+75% +$22 ﹤0.01% 7176
2023
Q3 		$23 Buy
+4
New +$27 ﹤0.01% 7143

Other funds holding NMTC

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase's NMTC Position: Q2 2025 in Review

JP Morgan Chase sold out of NeuroOne Medical Technologies (NMTC) in Q2 2025, closing a stake of 10 shares — an estimated $52 sold.

JP Morgan Chase first reported a position in NMTC in Q3 2023 and held it in 7 quarters. The position peaked at $68 in Q3 2024. 30 funds tracked by Wall St. Rank hold NMTC as of Q2 2025.

  • JP Morgan Chase reported no remaining NeuroOne Medical Technologies position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 10 NeuroOne Medical Technologies shares in Q2 2025, an estimated $52.
  • JP Morgan Chase first reported a position in NeuroOne Medical Technologies in Q3 2023 and held it in 7 quarters.
  • JP Morgan Chase's NeuroOne Medical Technologies position peaked at $68 in Q3 2024.
  • 30 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.